{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T02:16:18Z","timestamp":1789784178307,"version":"4.0.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02626-3","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:01:10Z","timestamp":1774310470000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Rationale for multi-epitope TGF\u03b2 vaccination in pancreatic cancer: evidence from immunologic and clinical correlates"],"prefix":"10.1038","volume":"11","author":[{"given":"Josephine Hallundb\u00e6k","family":"Ruders","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamaila Munir","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasmus Erik Johansson","family":"Mortensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1379-2647","authenticated-orcid":false,"given":"\u00d6zcan","family":"Met","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1744-1069","authenticated-orcid":false,"given":"Mikkel","family":"Byrdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2891-0762","authenticated-orcid":false,"given":"Inna Markovna","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susann","family":"Theile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3764-8578","authenticated-orcid":false,"given":"Morten Orebo","family":"Holmstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2914-9605","authenticated-orcid":false,"given":"Mads Hald","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"2626_CR1","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3390\/diagnostics12010124","volume":"12","author":"B Healey Bird","year":"2022","unstructured":"Healey Bird, B. et al. Cancer immunotherapy with immune checkpoint inhibitors-biomarkers of response and toxicity; current limitations and future promise. Diagnostics (Basel) 12, 124 (2022).","journal-title":"Diagnostics (Basel)"},{"key":"2626_CR2","first-page":"1","volume":"9","author":"B Wu","year":"2024","unstructured":"Wu, B., Zhang, B., Li, B., Wu, H. & Jiang, M. Cold and hot tumors: from molecular mechanisms to targeted therapy. Signal Transduct. Target Ther. 9, 1\u201365 (2024).","journal-title":"Signal Transduct. Target Ther."},{"key":"2626_CR3","first-page":"1","volume":"8","author":"Y Ju","year":"2024","unstructured":"Ju, Y. et al. Barriers and opportunities in pancreatic cancer immunotherapy. NPJ Precis. Oncol. 8, 1\u201318 (2024).","journal-title":"NPJ Precis. Oncol."},{"key":"2626_CR4","doi-asserted-by":"publisher","first-page":"4298","DOI":"10.3748\/wjg.v27.i27.4298","volume":"27","author":"JX Hu","year":"2021","unstructured":"Hu, J. X. et al. Pancreatic cancer: a review of epidemiology, trend, and risk factors. World J. Gastroenterol. 27, 4298\u20134321 (2021).","journal-title":"World J. Gastroenterol."},{"key":"2626_CR5","doi-asserted-by":"publisher","first-page":"5086","DOI":"10.3390\/cancers13205086","volume":"13","author":"DR Principe","year":"2020","unstructured":"Principe, D. R., Timbers, K. E., Atia, L. G., Koch, R. M. & Rana, A. TGF\u03b2 signaling in the pancreatic tumor microenvironment. Cancers (Basel) 13, 5086 (2020).","journal-title":"Cancers (Basel)"},{"key":"2626_CR6","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s00281-016-0593-x","volume":"39","author":"MH Andersen","year":"2017","unstructured":"Andersen, M. H. Anti-regulatory T cells. Semin. Immunopathol. 39, 317\u2013326 (2017).","journal-title":"Semin. Immunopathol."},{"key":"2626_CR7","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1158\/0008-5472.CAN-12-3507","volume":"73","author":"S Munir","year":"2013","unstructured":"Munir, S. et al. HLA-restricted CTL that are specific for the immune checkpoint ligand PD-L1 occur with high frequency in cancer patients. Cancer Res. 73, 1764\u20131776 (2013).","journal-title":"Cancer Res."},{"key":"2626_CR8","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1182\/blood-2010-06-288498","volume":"117","author":"RB S\u00f8rensen","year":"2011","unstructured":"S\u00f8rensen, R. B. et al. Indoleamine 2,3-dioxygenase-specific, cytotoxic T cells as immune regulators. Blood 117, 2200\u20132210 (2011).","journal-title":"Blood"},{"key":"2626_CR9","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1404215","volume":"7","author":"E Martinenaite","year":"2017","unstructured":"Martinenaite, E. et al. Frequent adaptive immune responses against arginase-1. Oncoimmunology 7, e1404215 (2017).","journal-title":"Oncoimmunology"},{"key":"2626_CR10","doi-asserted-by":"publisher","first-page":"1771142","DOI":"10.1080\/2162402X.2020.1771142","volume":"9","author":"SE Weis-Banke","year":"2020","unstructured":"Weis-Banke, S. E. et al. The metabolic enzyme arginase-2 is a potential target for novel immune modulatory vaccines. Oncoimmunology 9, 1771142 (2020).","journal-title":"Oncoimmunology"},{"key":"2626_CR11","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41423-020-00593-5","volume":"18","author":"MO Holmstr\u00f6m","year":"2021","unstructured":"Holmstr\u00f6m, M. O. et al. Cytotoxic T cells isolated from healthy donors and cancer patients kill TGF\u03b2-expressing cancer cells in a TGF\u03b2-dependent manner. Cell Mol. Immunol. 18, 415\u2013426 (2021).","journal-title":"Cell Mol. Immunol."},{"key":"2626_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005491","volume":"10","author":"M Perez-Penco","year":"2022","unstructured":"Perez-Penco, M. et al. TGF\u03b2-derived immune modulatory vaccine: targeting the immunosuppressive and fibrotic tumor microenvironment in a murine model of pancreatic cancer. J. Immunother. Cancer 10, e005491 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"2626_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006432","volume":"11","author":"REJ Mortensen","year":"2023","unstructured":"Mortensen, R. E. J. et al. Pre-existing TGF-\u03b2-specific T-cell immunity in patients with pancreatic cancer predicts survival after checkpoint inhibitors combined with radiotherapy. J. Immunother. Cancer 11, e006432 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"2626_CR14","unstructured":"Nivolumab with Ipilimumab Combined with TGF\u03b2-15 Peptide Vaccine and Radiotherapy for Pancreatic Cancer (CheckVAC) (NCT05721846). ClinicalTrials.gov. (2024)."},{"key":"2626_CR15","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ejca.2022.11.035","volume":"180","author":"IM Chen","year":"2023","unstructured":"Chen, I. M. et al. Phase 2 study of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy in patients with refractory pancreatic cancer (TRIPLE-R). Eur. J. Cancer 180, 125\u2013133 (2023).","journal-title":"Eur. J. Cancer"},{"key":"2626_CR16","doi-asserted-by":"publisher","first-page":"3045","DOI":"10.3390\/cancers12103045","volume":"12","author":"MO Holmstr\u00f6m","year":"2020","unstructured":"Holmstr\u00f6m, M. O. & Andersen, M. H. Healthy donors harbor memory T cell responses to RAS neo-antigens. Cancers (Basel) 12, 3045 (2020).","journal-title":"Cancers (Basel)"},{"key":"2626_CR17","doi-asserted-by":"publisher","first-page":"3180","DOI":"10.1200\/JCO.21.02511","volume":"40","author":"IM Chen","year":"2022","unstructured":"Chen, I. M. et al. Randomized phase II study of nivolumab with or without ipilimumab combined with stereotactic body radiotherapy for refractory metastatic pancreatic cancer (CheckPAC). J. Clin. Oncol. 40, 3180\u20133189 (2022).","journal-title":"J. Clin. Oncol."},{"key":"2626_CR18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41571-020-0403-1","volume":"18","author":"R Derynck","year":"2021","unstructured":"Derynck, R., Turley, S. J. & Akhurst, R. J. TGF\u03b2 biology in cancer progression and immunotherapy. Nat. Rev. Clin. Oncol. 18, 9\u201334 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2626_CR19","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1093\/abbs\/gmx123","volume":"50","author":"F Xie","year":"2018","unstructured":"Xie, F., Ling, L., van Dam, H., Zhou, F. & Zhang, L. TGF-\u03b2 signaling in cancer metastasis. Acta Biochim. Biophys. Sin. (Shanghai) 50, 121\u2013132 (2018).","journal-title":"Acta Biochim. Biophys. Sin. (Shanghai)"},{"key":"2626_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01569-x","volume":"21","author":"D Peng","year":"2022","unstructured":"Peng, D., Fu, M., Wang, M., Wei, Y. & Wei, X. Targeting TGF-\u03b2 signal transduction for fibrosis and cancer therapy. Mol. Cancer 21, 104 (2022).","journal-title":"Mol. Cancer"},{"key":"2626_CR21","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1053\/j.gastro.2023.05.038","volume":"165","author":"L Qiang","year":"2023","unstructured":"Qiang, L. et al. Transforming growth factor-\u03b2 blockade in pancreatic cancer enhances sensitivity to combination chemotherapy. Gastroenterology 165, 874\u2013890 (2023).","journal-title":"Gastroenterology"},{"key":"2626_CR22","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1038\/s41416-018-0246-z","volume":"119","author":"D Melisi","year":"2018","unstructured":"Melisi, D. et al. Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer. Br. J. Cancer 119, 1208\u20131214 (2018).","journal-title":"Br. J. Cancer"},{"key":"2626_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002068","volume":"9","author":"D Melisi","year":"2021","unstructured":"Melisi, D. et al. Safety and activity of the TGF\u03b2 receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer. J. Immunother. Cancer 9, e002068 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"2626_CR24","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1016\/0016-5085(93)91084-U","volume":"105","author":"H Friess","year":"1993","unstructured":"Friess, H. et al. Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology 105, 1846\u20131856 (1993).","journal-title":"Gastroenterology"},{"key":"2626_CR25","doi-asserted-by":"publisher","first-page":"e1005895","DOI":"10.1371\/journal.ppat.1005895","volume":"12","author":"E Panagioti","year":"2016","unstructured":"Panagioti, E. et al. The breadth of synthetic long peptide vaccine-induced CD8+ T cell responses determines the efficacy against mouse cytomegalovirus infection. PLoS Pathog. 12, e1005895 (2016).","journal-title":"PLoS Pathog."},{"key":"2626_CR26","doi-asserted-by":"publisher","first-page":"6011","DOI":"10.7150\/thno.38742","volume":"10","author":"X Chen","year":"2020","unstructured":"Chen, X., Yang, J., Wang, L. & Liu, B. Personalized neoantigen vaccination with synthetic long peptides: recent advances and future perspectives. Theranostics 10, 6011\u20136023 (2020).","journal-title":"Theranostics"},{"key":"2626_CR27","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1158\/2326-6066.CIR-18-0310","volume":"7","author":"A Gonzalez-Junca","year":"2019","unstructured":"Gonzalez-Junca, A. et al. Autocrine TGF\u03b2 is a survival factor for monocytes and drives immunosuppressive lineage commitment. Cancer Immunol. Res 7, 306\u2013320 (2019).","journal-title":"Cancer Immunol. Res"},{"key":"2626_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-025-01118-9","volume":"10","author":"BA Shah","year":"2025","unstructured":"Shah, B. A., Holden, J. A., Lenzo, J. C., Hadjigol, S. & O\u2019Brien-Simpson, N. M. Multi-disciplinary approaches paving the way for clinically effective peptide vaccines for cancer. Npj Vaccines 10, 68 (2025).","journal-title":"Npj Vaccines"},{"key":"2626_CR29","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1016\/j.cell.2020.05.017","volume":"181","author":"DY Oh","year":"2020","unstructured":"Oh, D. Y. et al. Intratumoral CD4+ T cells mediate anti-tumor cytotoxicity in human bladder cancer. Cell 181, 1612\u20131625 (2020).","journal-title":"Cell"},{"key":"2626_CR30","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/s42003-023-04812-3","volume":"6","author":"W Lin","year":"2023","unstructured":"Lin, W. et al. Human CD4 cytotoxic T lymphocytes mediate potent tumor control in humanized immune system mice. Commun. Biol. 6, 447 (2023).","journal-title":"Commun. Biol."},{"key":"2626_CR31","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1038\/mt.2008.200","volume":"16","author":"K Karik\u00f3","year":"2008","unstructured":"Karik\u00f3, K. et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol. Ther. 16, 1833\u20131840 (2008).","journal-title":"Mol. Ther."},{"key":"2626_CR32","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1038\/mt.2015.103","volume":"23","author":"A Thess","year":"2015","unstructured":"Thess, A. et al. Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals. Mol. Ther. 23, 1456\u20131464 (2015).","journal-title":"Mol. Ther."},{"key":"2626_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00760-5","volume":"8","author":"C Xie","year":"2023","unstructured":"Xie, C., Yao, R. & Xia, X. The advances of adjuvants in mRNA vaccines. NPJ Vaccines 8, 162 (2023).","journal-title":"NPJ Vaccines"},{"key":"2626_CR34","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13046-019-1084-4","volume":"38","author":"L Aurisicchio","year":"2019","unstructured":"Aurisicchio, L. et al. Poly-specific neoantigen-targeted cancer vaccines delay the growth of patient-derived tumors. J. Exp. Clin. Cancer Res. 38, 78 (2019).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2626_CR35","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/s41435-024-00305-3","volume":"25","author":"W Zhang","year":"2024","unstructured":"Zhang, W. et al. Neoantigen-specific mRNA\/DC vaccines for effective anticancer immunotherapy. Genes Immun. 25, 514\u2013524 (2024).","journal-title":"Genes Immun."},{"key":"2626_CR36","doi-asserted-by":"publisher","first-page":"233","DOI":"10.2147\/OTT.S493643","volume":"18","author":"KA Sheikh","year":"2025","unstructured":"Sheikh, K. A. et al. Exploring TGF-\u03b2 signaling in cancer progression: prospects and therapeutic strategies. Onco Targets Ther. 18, 233\u2013262 (2025).","journal-title":"Onco Targets Ther."},{"key":"2626_CR37","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1158\/1078-0432.CCR-17-3322","volume":"24","author":"SC Formenti","year":"2018","unstructured":"Formenti, S. C. et al. Focal irradiation and systemic transforming growth factor \u03b2 blockade in metastatic breast cancer. Clin. Cancer Res. 24, 2493\u20132504 (2018).","journal-title":"Clin. Cancer Res."},{"key":"2626_CR38","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.145651","volume":"6","author":"L Varricchio","year":"2021","unstructured":"Varricchio, L. et al. TGF-\u03b21 protein trap AVID200 beneficially affects hematopoiesis and bone marrow fibrosis in myelofibrosis. JCI Insights 6, e145651 (2021).","journal-title":"JCI Insights"},{"key":"2626_CR39","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1002\/ibd.21167","volume":"16","author":"Y Ma","year":"2010","unstructured":"Ma, Y. et al. Targeting TGF-beta1 by employing a vaccine ameliorates fibrosis in a mouse model of chronic colitis. Inflamm. Bowel Dis. 16, 1040\u20131050 (2010).","journal-title":"Inflamm. Bowel Dis."},{"key":"2626_CR40","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s10549-010-0844-9","volume":"125","author":"\u00d6 Met","year":"2011","unstructured":"Met, \u00d6, Balslev, E., Flyger, H. & Svane, I. M. High immunogenic potential of p53 mRNA-transfected dendritic cells in patients with primary breast cancer. Breast Cancer Res. Treat. 125, 395\u2013406 (2011).","journal-title":"Breast Cancer Res. Treat."},{"key":"2626_CR41","unstructured":"Thermo Fisher Scientific. Stealth RNAi siRNA\u2014Benefits of Stealth siRNA next-generation chemistry. www.thermofisher.com\/us\/en\/home\/life-science\/rnai\/synthetic-rnai-analysis\/stealth-rnai-technology.html (2025)."},{"key":"2626_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0166-4","volume":"9","author":"MO Holmstr\u00f6m","year":"2019","unstructured":"Holmstr\u00f6m, M. O. et al. High frequencies of circulating memory T cells specific for calreticulin exon 9 mutations in healthy individuals. Blood Cancer J. 9, 8 (2019).","journal-title":"Blood Cancer J."},{"key":"2626_CR43","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1007\/s00262-010-0875-4","volume":"59","author":"Z Moodie","year":"2010","unstructured":"Moodie, Z. et al. Response definition criteria for ELISPOT assays revisited. Cancer Immunol. Immunother. 59, 1489\u20131501 (2010).","journal-title":"Cancer Immunol. Immunother."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02626-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02626-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02626-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T03:02:21Z","timestamp":1774407741000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02626-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2626"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02626-3","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"assertion":[{"value":"9 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Mads Hald Andersen has developed inventions utilizing peptides derived from TGF\u03b2 for vaccination purposes and for predicting patient treatment responses. By the Danish Law of Public Inventions at Public Research Institutions, the rights to the invention have been assigned to Copenhagen University Hospital, Herlev. The Capital Region of Denmark subsequently assigned these rights to IO Biotech, which filed the corresponding patent application. Mads Hald Andersen is a founder of IO Biotech, serves on its scientific advisory board, and is a shareholder. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Regarding the healthy donor samples, per Danish Law on Research Ethics (\u00a714, Section 3), anonymized material does not require ethics approval.This study included patient samples and was approved under Clinical Study Protocol CheckPAC, Version 5 (12 March 2021). Ethical and regulatory approvals were obtained from the Danish Medicines Authority (L\u00e6gemiddelstyrelsen; EudraCT No. 2016-001883-12), the Regional Ethics Committee for the Capital Region of Denmark (ID H-16031247), and the Danish Knowledge Centre for Data Reviews (Videnscenter for Dataanmeldelser; journal no. P-2021-216). All participants provided written informed consent in accordance with the Declaration of Helsinki prior to participation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent"}}],"article-number":"107"}}